View Item 

Show simple item record

Biomarkers in advanced larynx cancer

dc.contributor.authorBradford, Carol R.en_US
dc.contributor.authorKumar, Bhavnaen_US
dc.contributor.authorBellile, Emilyen_US
dc.contributor.authorLee, Juliaen_US
dc.contributor.authorTaylor, Jeremyen_US
dc.contributor.authorD'Silva, Nishaen_US
dc.contributor.authorCordell, Kitrinaen_US
dc.contributor.authorKleer, Celinaen_US
dc.contributor.authorKupfer, Robbien_US
dc.contributor.authorKumar, Pawanen_US
dc.contributor.authorUrba, Susanen_US
dc.contributor.authorWorden, Francisen_US
dc.contributor.authorEisbruch, Avrahamen_US
dc.contributor.authorWolf, Gregory T.en_US
dc.contributor.authorTeknos, Theodoros N.en_US
dc.contributor.authorPrince, Mark E.P.en_US
dc.contributor.authorChepeha, Douglas B.en_US
dc.contributor.authorHogikyan, Norman D.en_US
dc.contributor.authorMoyer, Jeffrey S.en_US
dc.contributor.authorCarey, Thomas E.en_US
dc.date.accessioned2014-01-08T20:34:19Z
dc.date.available2015-03-02T14:35:34Zen_US
dc.date.issued2014-01en_US
dc.identifier.citationBradford, Carol R.; Kumar, Bhavna; Bellile, Emily; Lee, Julia; Taylor, Jeremy; D'Silva, Nisha; Cordell, Kitrina; Kleer, Celina; Kupfer, Robbi; Kumar, Pawan; Urba, Susan; Worden, Francis; Eisbruch, Avraham; Wolf, Gregory T.; Teknos, Theodoros N.; Prince, Mark E.P.; Chepeha, Douglas B.; Hogikyan, Norman D.; Moyer, Jeffrey S.; Carey, Thomas E. (2014). "Biomarkers in advanced larynx cancer." The Laryngoscope 124(1): 179-187.en_US
dc.identifier.issn0023-852Xen_US
dc.identifier.issn1531-4995en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/102058
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherP53en_US
dc.subject.otherLaryngeal Cancer or Carcinomaen_US
dc.subject.otherBiomarkersen_US
dc.subject.otherEGFRen_US
dc.subject.otherCyclin D1en_US
dc.titleBiomarkers in advanced larynx canceren_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOtolaryngologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/102058/1/lary24245.pdf
dc.identifier.doi10.1002/lary.24245en_US
dc.identifier.sourceThe Laryngoscopeen_US
dc.identifier.citedreferenceAng KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62: 7350 – 7356.en_US
dc.identifier.citedreferenceJemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010; 60: 277 – 300. doi: 10.3322/caac.20073. Epub 2010.en_US
dc.identifier.citedreferenceInduction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991; 324: 1685 – 1690.en_US
dc.identifier.citedreferenceUrba S, Wolf GT. Organ preservation in multimodality therapy of head and neck cancer. Hematol Oncol Clin North Am 1991; 5: 713 – 724.en_US
dc.identifier.citedreferenceUrba S, Wolf G, Eisbruch A, et al. Single‐cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J Clin Oncol 2006; 24: 593 – 598.en_US
dc.identifier.citedreferencevan Oijen MG, Slootweg PJ. Gain‐of‐function mutations in the tumor suppressor gene p53. Clin Cancer Res 2000; 6: 2138 – 2145.en_US
dc.identifier.citedreferenceVillunger A, Michalak EM, Coultas L, et al. p53‐ and drug‐induced apoptotic responses mediated by BH3‐only proteins puma and noxa. Science 2003; 302: 1036 – 1038.en_US
dc.identifier.citedreferenceReed JC, Miyashita T, Takayama S, et al. BCL‐2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 1996; 60: 23 – 32.en_US
dc.identifier.citedreferenceChao DT, Korsmeyer SJ. BCL‐2 family: regulators of cell death. Annu Rev Immunol 1998; 16: 395 – 419.en_US
dc.identifier.citedreferenceMinn AJ, Rudin CM, Boise LH, Thompson CB. Expression of bcl‐xL can confer a multidrug resistance phenotype. Blood 1995; 86: 1903 – 1910.en_US
dc.identifier.citedreferenceWillis SN, Adams JM. Life in the balance: how BH3‐only proteins induce apoptosis. Curr Opin Cell Biol 2005; 17: 617 – 625.en_US
dc.identifier.citedreferenceTrask DK, Wolf GT, Bradford CR, et al. Expression of Bcl‐2 family proteins in advanced laryngeal squamous cell carcinoma: correlation with response to chemotherapy and organ preservation. Laryngoscope 2002; 112: 638 – 644.en_US
dc.identifier.citedreferenceAdams JM, Cory S. The Bcl‐2 protein family: arbiters of cell survival. Science 1998; 281: 1322 – 1326.en_US
dc.identifier.citedreferenceKristiansen G, Denkert C, Schluns K, Dahl E, Pilarsky C, Hauptmann S. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol 2002; 161: 1215 – 1221.en_US
dc.identifier.citedreferenceWeichert W, Denkert C, Burkhardt M, et al. Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin Cancer Res 2005; 11: 6574 – 6581.en_US
dc.identifier.citedreferenceKristiansen G, Pilarsky C, Pervan J, et al. CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate 2004; 58: 183 – 192.en_US
dc.identifier.citedreferenceKristiansen G, Schluns K, Yongwei Y, Denkert C, Dietel M, Petersen I. CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. Br J Cancer 2003; 88: 231 – 236.en_US
dc.identifier.citedreferenceKristiansen G, Winzer KJ, Mayordomo E, et al. CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res 2003; 9: 4906 – 4913.en_US
dc.identifier.citedreferenceKumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV Titer, Bcl‐xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008; 26: 3128 – 3137.en_US
dc.identifier.citedreferenceMaurizi M, Almadori G, Ferrandina G, et al. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer 1996; 74: 1253 – 1257.en_US
dc.identifier.citedreferenceVogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307 – 310.en_US
dc.identifier.citedreferencePiette J, Neel H, Marechal V. Mdm2: keeping p53 under control. Oncogene 1997; 15: 1001 – 1010.en_US
dc.identifier.citedreferencePrives C. Signaling to p53: breaking the MDM2‐p53 circuit. Cell 1998; 95: 5 – 8.en_US
dc.identifier.citedreferenceLeu JI, Dumont P, Hafey M, Murphy ME, George DL. Mitochondrial p53 activates Bak and causes disruption of a Bak‐Mcl1 complex. Nat Cell Biol 2004; 6: 443 – 450.en_US
dc.identifier.citedreferenceOndrey FG, Dong G, Sunwoo J, et al. Constitutive activation of transcription factors NF‐(kappa)B, AP‐1, and NF‐IL6 in human head and neck squamous cell carcinoma cell lines that express pro‐inflammatory and pro‐angiogenic cytokines. Mol Carcinog 1999; 26: 119 – 129.en_US
dc.identifier.citedreferenceKleer CG, Griffith KA, Sabel MS, et al. RhoC‐GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast. Breast Cancer Res Treat 2005; 93: 101 – 110.en_US
dc.identifier.citedreferenceIslam M, Lin G, Brenner JC, et al. RhoC expression and head and neck cancer metastasis. Mol Cancer Res 2009; 7: 1771 – 1780.en_US
dc.identifier.citedreferenceBoone B, Van Gele M, Lambert J, Haspeslagh M, Brochez L. The role of RhoC in growth and metastatic capacity of melanoma. J Cutan Pathol 2009; 36: 629 – 636.en_US
dc.identifier.citedreferenceXu JH, Wang AX, Huang HZ, Wang JG, Pan CB, Zhang B. Survivin shRNA induces caspase‐3‐dependent apoptosis and enhances cisplatin sensitivity in squamous cell carcinoma of the tongue. Oncol Res 2010; 18: 377 – 385.en_US
dc.identifier.citedreferenceKleer CG, Teknos TN, Islam M, et al. RhoC GTPase expression as a potential marker of lymph node metastasis in squamous cell carcinomas of the head and neck. Clin Cancer Res 2006; 12: 4485 – 4490.en_US
dc.identifier.citedreferenceSpiro RH, Guillamondegui O Jr, Paulino AF, Huvos AG. Pattern of invasion and margin assessment in patients with oral tongue cancer. Head Neck 1999; 21: 408 – 413.en_US
dc.identifier.citedreferenceCarey VJ. Using hypertext and the Internet for structure and management of observational studies. Stat Med 1997; 16: 1667 – 1682.en_US
dc.identifier.citedreferenceDuffey DC, Chen Z, Dong G, et al. Expression of a dominant‐negative mutant inhibitor‐kappaBalpha of nuclear factor‐kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res 1999; 59: 3468 – 3474.en_US
dc.identifier.citedreferenceDong G, Chen Z, Kato T, Van Waes C. The host environment promotes the constitutive activation of nuclear factor‐kappaB and proinflammatory cytokine expression during metastatic tumor progression of murine squamous cell carcinoma. Cancer Res 1999; 59: 3495 – 3504.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
lary24245.pdf
Size:
335.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.